Lora Reynolds
Family · Abingdon, VANPI 1063838654
Payments from drug & device makers
Across 654 payments — averaging $64.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$32K
- Medtronic$2K
- Lilly USA, LLC$2K
- Dexcom, Inc.$1K
- AstraZeneca$780
- Abbott$679
- plus $4K from 28 others
What the payments were for
- Speaking & faculty fees$27,91366%
- Travel & lodging$2,7617%
- Food & beverage$11,44027%
- Education$710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 162 | $31,861 |
| Medtronic | 45 | $2,460 |
| Lilly USA, LLC | 102 | $1,537 |
| Dexcom, Inc. | 53 | $1,103 |
| AstraZeneca | 51 | $780 |
| Abbott | 42 | $679 |
| Bayer | 36 | $498 |
| Boehringer Ingelheim | 25 | $463 |
| Tandem Diabetes Care, Inc. | 7 | $424 |
| Amgen(2 entities) | 22 | $329 |
| Corcept Therapeutics | 16 | $324 |
| Xeris Pharmaceuticals, Inc. | 14 | $261 |
| Novartis | 12 | $246 |
| Sanofi-aventis U.S. LLC | 15 | $245 |
| Esperion Therapeutics, Inc. | 9 | $204 |
| Recordati_rare_diseases_inc. | 7 | $127 |
| Insulet Corporation | 7 | $101 |
| Antares Pharma, Inc. | 6 | $101 |
| Amarin Pharma, Inc. | 5 | $72 |
| Sequel Med Tech, LLC | 2 | $60 |
| Kyowa Kirin, Inc. | 2 | $38 |
| Madrigal Pharmaceuticals | 1 | $36 |
| Mannkind Corporation | 1 | $31 |
| Halozyme Inc | 2 | $30 |
| Ionis Pharmaceuticals, Inc. | 1 | $26 |
| BD | 1 | $23 |
| Vifor Pharma, Inc. | 1 | $23 |
| BETA Bionics, Inc. | 1 | $18 |
| GSK | 1 | $17 |
| AbbVie | 1 | $16 |
| Clarus Therapeutics Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Collegium Pharmaceutical, Inc. | 1 | $12 |
| Zealand Pharma US, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$20,366
- Ozempic$7,690
- MINIMED 780G$1,420
- Wegovy$121
- DEXCOM G6 TRANSMITTER$115
- DEXCOM G7 GSS (161)$109
How this compares
$42,186 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 455 | $529,268 |
| TrulicityDulaglutide | 246 | $314,513 |
| MounjaroTirzepatide | 224 | $264,210 |
| Humalog Kwikpen U-200Insulin Lispro | 69 | $165,204 |
| JardianceEmpagliflozin | 185 | $146,695 |
| FarxigaDapagliflozin Propanediol | 180 | $143,650 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 100 | $142,243 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 98 | $96,604 |
| Humalog Kwikpen U-100Insulin Lispro | 240 | $86,951 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 42 | $85,661 |
| Novolog FlexpenInsulin Aspart | 254 | $83,138 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 61 | $77,854 |
| Tresiba Flextouch U-200Insulin Degludec | 73 | $59,247 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 60 | $52,033 |
| Tresiba Flextouch U-100Insulin Degludec | 71 | $51,031 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $1,537 | $619,479662 claims |
| Novo NordiskOzempic, Novolog, Xultophy 100-3.6 | $31,861 | $572,343570 claims |
| Boehringer IngelheimJardiance | $463 | $146,695185 claims |
| AstraZenecaFarxiga | $780 | $143,650180 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $245 | $106,106158 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.
Other family in Abingdon
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
- Adam MedlinHampton$67K
- Casey SharpDanville$63K
- Norman JacobowitzManassas$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.